GlassScriptPhysician profile
Rachel D Lee
NPI 1003830159
$4,197.21
in general payments reported to CMS, 2019-2025
31 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 92% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $82.78 · 2021: $461 · 2022: $559 · 2023: $873 · 2024: $556 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,525 · Travel and Lodging: $1,247 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,524.85 |
| Travel and Lodging | $1,246.96 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,246.96 | 2023-2025 | Da Vinci Surgical System |
| Abbvie INC. | $392.08 | 2019-2023 | |
| Daiichi Sankyo INC. | $334.51 | 2019-2025 | Injectafer |
| Sumitomo Pharma America, INC. | $239.86 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $219.48 | 2019-2025 | |
| Organon LLC | $199.23 | 2021-2025 | Nexplanon, Jada System |
| Astellas Pharma US INC | $180.89 | 2023-2025 | Veozah |
| Myovant Sciences INC. | $178.90 | 2021-2022 | |
| Pfizer INC. | $125.87 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $105.75 | 2025 | Keveyis |
| Merck Sharp & Dohme LLC | $99.74 | 2019-2021 | |
| Minerva Surgical, INC | $93.75 | 2019-2023 | |
| Lilly USA, LLC | $88.80 | 2023-2024 | Olumiant, Taltz |
| Aspira Women'S Health INC | $79.99 | 2022-2024 | Ova1 |
| Hologic Sales and Service, LLC | $74.14 | 2019-2024 | Aptima |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $62.24 | 2019 | |
| Millicent US INC | $60.43 | 2024-2025 | Intrarosa, Femring |
| Biogen, INC. | $60.25 | 2024-2025 | Zurzuvae |
| Meditrina | $54.28 | 2023-2025 | |
| Evofem Biosciences, INC. | $44.54 | 2022 | |
| Shield Therapeutics INC | $41.46 | 2024-2025 | |
| Optumhealth Care Solutions, LLC | $41.43 | 2024 | Vivify Health Care Team Portal 001, Eitan Medical |
| Coopersurgical, INC. | $40.15 | 2025 | Paragard T 380a, Ally II Ups |
| Coloplast Corp | $21.81 | 2025 | |
| Mylan Pharmaceuticals INC. | $20.50 | 2019 | |
| Scynexis, INC. | $20.45 | 2022 | |
| Mimedx Group, INC. | $16.52 | 2024 | |
| Mayne Pharma Commercial LLC | $15.23 | 2025 | |
| Agile Therapeutics, INC. | $13.50 | 2022 | |
| Cook Medical LLC | $12.85 | 2021 | |
| Therapeuticsmd, INC. | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.